Innohep (Tinzaparin Sodium)

Innohep, a low molecular weight heparin, is used in several thrombo‑embolic conditions.

• Deep vein thrombosis (surgical prophylaxis): prevents clot formation in postoperative patients.
• Acute deep vein thrombosis (treatment): facilitates clot resolution and reduces propagation.
• Pulmonary embolism (prevention and treatment): lowers the risk of embolic events in at‑risk individuals.
• Medically ill patients (thrombo‑embolic prophylaxis): reduces incidence of venous thromboembolism during hospitalization.

• Tinzaparin sodium binds to antithrombin III, markedly enhancing its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This accelerated inhibition disrupts the conversion of prothrombin to thrombin and the generation of fibrin, thereby limiting clot formation while preserving a predictable anticoagulant profile characteristic of low molecular weight heparins.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects

• Injection site erythema or bruising: mild local irritation after subcutaneous administration.
• Minor bleeding: occasional nosebleeds or gum bleeding that resolves spontaneously.
• Elevated liver enzymes: transient increase detected in routine labs.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening bleeding requiring medical intervention.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet decline with paradoxical clot risk.
• Spontaneous spinal or epidural hematoma: rare bleeding in the spinal canal, especially after neuraxial procedures.

Careful assessment is required before initiating therapy.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function.
• Bleeding risk: avoid in individuals with active bleeding, recent surgery, or known coagulopathy.
• Pregnancy and lactation: use only if the potential benefit outweighs potential risk, as safety data are limited.
• Concomitant anticoagulants: increase monitoring when combined with other blood‑thinning agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin may interact with several drug classes.

Major Interactions (Avoid)

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk.
• Antiplatelet agents (e.g., clopidogrel, aspirin) in high‑dose regimens: synergistic hemorrhagic effect.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may prolong bleeding time.
• Thrombolytic agents (e.g., alteplase): enhanced anticoagulant effect requiring close observation.
• Certain antibiotics (e.g., quinolones) that affect platelet function: monitor for bleeding signs.